Skip to main content

Table 2 Somatic mutation genotyping results by oestrogen receptor and progesterone receptor status and treatment arm

From: Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies

  

PIK3CA mutated

ERBB mutated

PIK3CA/ERBB mutateda

Tumour group

Total no. of tumours

No. of tumours (%)

No. of tumours (%)

No. of tumours (%)

ER status

 Negative

29

8 (27.6)

1 (3.4)

8 (27.6)

 Positive

45

10 (22.2)

7 (15.6)

15 (33.3)

PR status

 Negative

43

9 (20.9)

5 (11.6)

14 (32.6)

 Positive

31

8 (25.8)

3 (9.7)

9 (29)

Treatment arm

 TCL

10

3 (30)

2 (20)

3 (30)

 TCH

32

9 (28.1)

2 (6.3)

10 (31.3)

 TCHL

32

6 (18.8)

4 (12.5)

10 (31.3)

  1. Abbreviations: ER Oestrogen receptor, PR Progesterone receptor, TCH Docetaxel, carboplatin, and trastuzumab, TCHL Docetaxel, carboplatin, trastuzumab, lapatinib, TCL Docetaxel, carboplatin, lapatinib
  2. Association of PIK3CA mutations, ERBB family mutations and combined PIK3CA/ERBB family mutations with ER and PR status. The mutation frequency in each treatment arm is also shown
  3. aThese numbers/percentages may not be a sum of PIK3CA and ERBB mutated because of mutation overlap